AZN vs. CYTK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AZN and CYTK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
AZN’s market capitalization of 430.65 billion USD is substantially larger than CYTK’s 4.14 billion USD, indicating a significant difference in their market valuations.
CYTK carries a higher beta at 0.59, indicating it’s more sensitive to market moves, while AZN (beta: 0.17) exhibits greater stability.
AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, CYTK is a standard domestic listing.
| Symbol | AZN | CYTK |
|---|---|---|
| Company Name | AstraZeneca PLC | Cytokinetics, Incorporated |
| Country | GB | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| CEO | Pascal Claude Roland Soriot | Robert I. Blum |
| Price | 69.45 USD | 34.66 USD |
| Market Cap | 430.65 billion USD | 4.14 billion USD |
| Beta | 0.17 | 0.59 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | May 12, 1993 | April 30, 2004 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of AZN and CYTK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
AZN
19.18%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
AZN’s Return on Equity of 19.18% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
CYTK
801.26%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
CYTK’s Return on Equity of 801.26% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Return on Invested Capital
AZN
10.93%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
AZN’s Return on Invested Capital of 10.93% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
CYTK
-49.75%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
CYTK has a negative Return on Invested Capital of -49.75%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
Net Profit Margin
AZN
14.14%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
AZN’s Net Profit Margin of 14.14% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
CYTK
-3,201.47%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
CYTK has a negative Net Profit Margin of -3,201.47%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin
AZN
19.21%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
AZN’s Operating Profit Margin of 19.21% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
CYTK
-2,943.30%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
CYTK has a negative Operating Profit Margin of -2,943.30%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | AZN | CYTK |
|---|---|---|
| Return on Equity (TTM) | 19.18% | 801.26% |
| Return on Assets (TTM) | 7.31% | -48.67% |
| Return on Invested Capital (TTM) | 10.93% | -49.75% |
| Net Profit Margin (TTM) | 14.14% | -3201.47% |
| Operating Profit Margin (TTM) | 19.21% | -2943.30% |
| Gross Profit Margin (TTM) | 81.41% | -1359.51% |
Financial Strength
Current Ratio
AZN
0.90
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
AZN’s Current Ratio of 0.90 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
CYTK
5.99
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
CYTK’s Current Ratio of 5.99 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
AZN
0.77
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
AZN’s Debt-to-Equity Ratio of 0.77 is typical for the Drug Manufacturers - General industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
CYTK
-2.97
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
CYTK has a Debt-to-Equity Ratio of -2.97, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
Interest Coverage Ratio
AZN
7.95
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
AZN’s Interest Coverage Ratio of 7.95 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
CYTK
-6.14
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
CYTK has a negative Interest Coverage Ratio of -6.14. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | AZN | CYTK |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 5.99 |
| Quick Ratio (TTM) | 0.70 | 5.99 |
| Debt-to-Equity Ratio (TTM) | 0.77 | -2.97 |
| Debt-to-Asset Ratio (TTM) | 0.30 | 0.63 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.49 | -1.39 |
| Interest Coverage Ratio (TTM) | 7.95 | -6.14 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for AZN and CYTK. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
AZN
1.87%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
AZN’s Dividend Yield of 1.87% is in the lower quartile for the Drug Manufacturers - General industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
AZN
63.60%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 63.60% is within the typical range for the Drug Manufacturers - General industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AZN | CYTK |
|---|---|---|
| Dividend Yield (TTM) | 1.87% | 0.00% |
| Dividend Payout Ratio (TTM) | 63.60% | 0.00% |
Valuation
Price-to-Earnings Ratio
AZN
28.12
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
At 28.12, AZN’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - General industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
CYTK
-6.68
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
CYTK has a negative P/E Ratio of -6.68. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
Forward P/E to Growth Ratio
AZN
2.56
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
AZN’s Forward PEG Ratio of 2.56 is within the middle range of its peers in the Drug Manufacturers - General industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
CYTK
11.70
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
CYTK’s Forward PEG Ratio of 11.70 is exceptionally high for the Biotechnology industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
Price-to-Sales Ratio
AZN
3.98
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
AZN’s P/S Ratio of 3.98 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
CYTK
215.39
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
With a P/S Ratio of 215.39, CYTK trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
AZN
5.33
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
CYTK
-15.42
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
Valuation at a Glance
| Symbol | AZN | CYTK |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.12 | -6.68 |
| Forward PEG Ratio (TTM) | 2.56 | 11.70 |
| Price-to-Sales Ratio (P/S, TTM) | 3.98 | 215.39 |
| Price-to-Book Ratio (P/B, TTM) | 5.33 | -15.42 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.59 | -10.11 |
| EV-to-EBITDA (TTM) | 13.82 | -9.41 |
| EV-to-Sales (TTM) | 4.46 | 252.72 |